Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage.
作者信息
Olsen Mark, Cook Sarah E, Huang Vanthida, Pedersen Niels, Murphy Brian G
机构信息
Department of Pharmaceutical Sciences, College of Pharmacy-Glendale, Midwestern University, 19555 N. 59th Avenue, Glendale, AZ 85308, USA.
Department of Pathology, Microbiology & Immunology, School of Veterinary Medicine, University of California, One Shields Avenue, Davis, CA 95616, USA.
出版信息
Int J Antimicrob Agents. 2020 Jun;55(6):105964. doi: 10.1016/j.ijantimicag.2020.105964. Epub 2020 Apr 3.
Abstract
摘要
相似文献
1
Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage.
Int J Antimicrob Agents. 2020 Jun;55(6):105964. doi: 10.1016/j.ijantimicag.2020.105964. Epub 2020 Apr 3.
2
Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
Antiviral Res. 2020 Oct;182:104927. doi: 10.1016/j.antiviral.2020.104927. Epub 2020 Sep 7.
3
Current status on treatment options for feline infectious peritonitis and SARS-CoV-2 positive cats.
Vet Q. 2020 Dec;40(1):322-330. doi: 10.1080/01652176.2020.1845917.
4
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
Nat Commun. 2020 Sep 4;11(1):4417. doi: 10.1038/s41467-020-18233-x.
5
Purposing Saikosaponins for the treatment of COVID-19.
Med Hypotheses. 2020 Jul;140:109782. doi: 10.1016/j.mehy.2020.109782. Epub 2020 Apr 23.
6
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
Nat Commun. 2020 Aug 27;11(1):4282. doi: 10.1038/s41467-020-18096-2.
7
Drugs and the renin-angiotensin system in covid-19.
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
8
Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.
Nat Rev Nephrol. 2020 Jun;16(6):305-307. doi: 10.1038/s41581-020-0279-4.
9
Potential Antiviral Options against SARS-CoV-2 Infection.
Viruses. 2020 Jun 13;12(6):642. doi: 10.3390/v12060642.
10
In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
Comput Biol Med. 2020 Sep;124:103936. doi: 10.1016/j.compbiomed.2020.103936. Epub 2020 Jul 28.
引用本文的文献
1
Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (M) as Potential COVID-19 Therapies.
Front Mol Biosci. 2022 Mar 14;9:781039. doi: 10.3389/fmolb.2022.781039. eCollection 2022.
2
Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
Comput Biol Med. 2022 Mar;142:105183. doi: 10.1016/j.compbiomed.2021.105183. Epub 2021 Dec 29.
3
Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives.
Front Mol Biosci. 2020 Nov 17;7:606393. doi: 10.3389/fmolb.2020.606393. eCollection 2020.
4
How close is SARS-CoV-2 to canine and feline coronaviruses?
J Small Anim Pract. 2020 Aug;61(8):523-526. doi: 10.1111/jsap.13207.
5
A Review of Current Interventions for COVID-19 Prevention.
Arch Med Res. 2020 Jul;51(5):363-374. doi: 10.1016/j.arcmed.2020.04.020. Epub 2020 Apr 30.
本文引用的文献
1
Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2.
Microbes Infect. 2020 May-Jun;22(4-5):221-225. doi: 10.1016/j.micinf.2020.03.003. Epub 2020 Mar 19.
2
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
3
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
4
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
5
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.
JAMA. 2020 Apr 21;323(15):1488-1494. doi: 10.1001/jama.2020.3204.
6
The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.
J Med Virol. 2020 Jun;92(6):552-555. doi: 10.1002/jmv.25728. Epub 2020 Mar 11.
7
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
J Med Virol. 2020 Jun;92(6):556-563. doi: 10.1002/jmv.25729. Epub 2020 Mar 12.
8
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
9
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
10
Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities.
Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868. doi: 10.1016/j.bbrc.2019.11.065. Epub 2019 Dec 2.
Zotero 插件